» Articles » PMID: 35437846

Current Treatments for Biofilm-associated Periprosthetic Joint Infection and New Potential Strategies

Overview
Journal J Orthop Res
Publisher Wiley
Specialty Orthopedics
Date 2022 Apr 19
PMID 35437846
Authors
Affiliations
Soon will be listed here.
Abstract

Periprosthetic joint infection (PJI) remains a devastating complication after total joint arthroplasty. Bacteria involved in these infections are notorious for adhering to foreign implanted surfaces and generating a biofilm matrix. These biofilms protect the bacteria from antibiotic treatment and the immune system making eradication difficult. Current treatment strategies including debridement, antibiotics, and implant retention, and one- and two-stage revisions still present a relatively high overall failure rate. One of the main shortcomings that has been associated with this high failure rate is the lack of a robust approach to treating bacterial biofilm. Therefore, in this review, we will highlight new strategies that have the potential to combat PJI by targeting biofilm integrity, therefore giving antibiotics and the immune system access to the internal network of the biofilm structure. This combination antibiofilm/antibiotic therapy may be a new strategy for PJI treatment while promoting implant retention.

Citing Articles

Bacteriophage Dosing and Its Effect on Bacterial Growth Suppression in a Model: An Study.

Young J, Shariyate M, Hedayatzadeh Razavi A, Nazarian A, Rodriguez E Phage (New Rochelle). 2025; 5(4):223-229.

PMID: 40045941 PMC: 11876813. DOI: 10.1089/phage.2024.0001.


Synergistic antibacterial drug elution from UHMWPE for load-bearing implants.

Inverardi N, Serafim M, Marzouca A, Fujino K, Ferreira M, Asik M J Mater Chem B. 2025; 13(7):2382-2399.

PMID: 39838885 PMC: 11874067. DOI: 10.1039/d4tb02672a.


Genomic Insights into Host Susceptibility to Periprosthetic Joint Infections: A Comprehensive Literature Review.

Lizcano J, Visperas A, Piuzzi N, Abdelbary H, Higuera-Rueda C Microorganisms. 2025; 12(12.

PMID: 39770689 PMC: 11728149. DOI: 10.3390/microorganisms12122486.


Prevention and Modern Strategies for Managing Methicillin-Resistant Staphylococcal Infections in Prosthetic Joint Infections (PJIs).

Kraus K, Mikzinski P, Widelski J, Paluch E Antibiotics (Basel). 2025; 13(12.

PMID: 39766540 PMC: 11672861. DOI: 10.3390/antibiotics13121151.


Periprosthetic joint infections: state-of-the-art.

Gehrke T, Citak M, Parvizi J, Budhiparama N, Akkaya M Arch Orthop Trauma Surg. 2024; 145(1):58.

PMID: 39694911 DOI: 10.1007/s00402-024-05627-5.


References
1.
Driesman A, Shen M, Feng J, Waren D, Slover J, Bosco J . Perioperative Chlorhexidine Gluconate Wash During Joint Arthroplasty Has Equivalent Periprosthetic Joint Infection Rates in Comparison to Betadine Wash. J Arthroplasty. 2019; 35(3):845-848. DOI: 10.1016/j.arth.2019.10.009. View

2.
Nurmohamed F, Dijk B, Veltman E, Hoekstra M, Rentenaar R, Weinans H . One-year infection control rates of a DAIR (debridement, antibiotics and implant retention) procedure after primary and prosthetic-joint-infection-related revision arthroplasty - a retrospective cohort study. J Bone Jt Infect. 2021; 6(4):91-97. PMC: 8129908. DOI: 10.5194/jbji-6-91-2021. View

3.
Sause W, Buckley P, Strohl W, Lynch A, Torres V . Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. Trends Pharmacol Sci. 2016; 37(3):231-241. PMC: 4764385. DOI: 10.1016/j.tips.2015.11.008. View

4.
Marques C, Davies D, Sauer K . Control of Biofilms with the Fatty Acid Signaling Molecule cis-2-Decenoic Acid. Pharmaceuticals (Basel). 2015; 8(4):816-35. PMC: 4695811. DOI: 10.3390/ph8040816. View

5.
McKenney D, Pouliot K, Wang Y, Murthy V, Ulrich M, DORING G . Vaccine potential of poly-1-6 beta-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis. J Biotechnol. 2000; 83(1-2):37-44. DOI: 10.1016/s0168-1656(00)00296-0. View